| CLINICAL STUDY |
The objective of the EARLY (Endothelin Antagonist tRial in miLdly sYmptomatic PAH patients) trial is to substantiate the potential of BoSentan in the treatment of patients with class II disease who are mildly symptomatic. The goal is to improve the patient’s exercise capacity and also to slow down disease progression. Results of this phase III, double-blind, placebo-controlled trial, which will be initiated in the second quarter of 2004, are expected in early 2006. |
| UPDATE | 03.04 |
| COMPANY | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |